KR102036938B1 - 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도 - Google Patents

뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도 Download PDF

Info

Publication number
KR102036938B1
KR102036938B1 KR1020147014713A KR20147014713A KR102036938B1 KR 102036938 B1 KR102036938 B1 KR 102036938B1 KR 1020147014713 A KR1020147014713 A KR 1020147014713A KR 20147014713 A KR20147014713 A KR 20147014713A KR 102036938 B1 KR102036938 B1 KR 102036938B1
Authority
KR
South Korea
Prior art keywords
synuclein
antibody
seq
antigen
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147014713A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095074A (ko
Inventor
안드레아스 바이호펜
토마스 엥버
얀 그림
Original Assignee
바이오겐 인터내셔널 뉴로사이언스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 인터내셔널 뉴로사이언스 게엠베하 filed Critical 바이오겐 인터내셔널 뉴로사이언스 게엠베하
Publication of KR20140095074A publication Critical patent/KR20140095074A/ko
Application granted granted Critical
Publication of KR102036938B1 publication Critical patent/KR102036938B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020147014713A 2011-11-02 2012-10-29 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도 Expired - Fee Related KR102036938B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
US61/554,924 2011-11-02
PCT/US2012/062430 WO2013066818A1 (en) 2011-11-02 2012-10-29 USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN

Publications (2)

Publication Number Publication Date
KR20140095074A KR20140095074A (ko) 2014-07-31
KR102036938B1 true KR102036938B1 (ko) 2019-10-25

Family

ID=48192661

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014713A Expired - Fee Related KR102036938B1 (ko) 2011-11-02 2012-10-29 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도

Country Status (13)

Country Link
US (3) US20140295465A1 (enExample)
EP (1) EP2773957B1 (enExample)
JP (1) JP6263473B2 (enExample)
KR (1) KR102036938B1 (enExample)
CN (2) CN104040342A (enExample)
AU (1) AU2012332814B2 (enExample)
BR (1) BR112014010664A2 (enExample)
CA (1) CA2854131C (enExample)
EA (1) EA034213B1 (enExample)
IL (1) IL232373B (enExample)
MX (1) MX356797B (enExample)
WO (1) WO2013066818A1 (enExample)
ZA (1) ZA201403879B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
EA039807B1 (ru) * 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US20110052498A1 (en) 2008-04-29 2011-03-03 Lars Lannfelt Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
WO1999050300A1 (en) * 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
JP2004502781A (ja) * 2000-07-07 2004-01-29 パナシア　ファーマシューティカルズ　インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
DK2099826T3 (da) 2007-01-05 2014-01-20 Univ Zuerich Anti-beta-amyloid-antistof og anvendelser deraf
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
US20110052498A1 (en) 2008-04-29 2011-03-03 Lars Lannfelt Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Also Published As

Publication number Publication date
ZA201403879B (en) 2018-11-28
US20180011112A1 (en) 2018-01-11
CN107091931A (zh) 2017-08-25
AU2012332814A1 (en) 2014-06-12
BR112014010664A2 (pt) 2017-04-25
CN104040342A (zh) 2014-09-10
EP2773957B1 (en) 2017-11-29
JP6263473B2 (ja) 2018-01-31
HK1201585A1 (en) 2015-09-04
EA034213B1 (ru) 2020-01-17
JP2014533357A (ja) 2014-12-11
CA2854131A1 (en) 2013-05-10
IL232373B (en) 2018-08-30
MX2014005378A (es) 2015-01-19
EP2773957A4 (en) 2015-06-24
IL232373A0 (en) 2014-06-30
WO2013066818A1 (en) 2013-05-10
CA2854131C (en) 2020-07-07
AU2012332814B2 (en) 2017-12-14
US20190094245A1 (en) 2019-03-28
EA201490883A1 (ru) 2014-10-30
NZ625217A (en) 2016-07-29
EP2773957A1 (en) 2014-09-10
KR20140095074A (ko) 2014-07-31
US20140295465A1 (en) 2014-10-02
MX356797B (es) 2018-06-14

Similar Documents

Publication Publication Date Title
KR102036938B1 (ko) 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도
CN106029093B (zh) 脑信号蛋白-4d结合分子治疗神经变性疾病的用途
JP7626416B2 (ja) 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
JP2019108359A (ja) アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用
HK1201585B (en) Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
NZ625217B2 (en) Use of an anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241022

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241022